Skip to main content
Clinical Trials/NCT03579121
NCT03579121
Completed
N/A

Genomic Opioid Optimization of Dosing and Selections (GOODS) Study

Mayo Clinic1 site in 1 country76 target enrollmentOctober 12, 2018

Overview

Phase
N/A
Intervention
Not specified
Conditions
Perioperative/Postoperative Complications
Sponsor
Mayo Clinic
Enrollment
76
Locations
1
Primary Endpoint
Change in Overall Benefit of Analgesic Score (OBAS)
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The researchers are conducting this study to see if pharmacogenomic testing before surgery helps the doctor to choose which medications will work best for the patient.

Detailed Description

Participants, undergoing total knee replacements, will be randomized into two groups. Both groups will receive pharmacogenomics (PGx) testing preoperatively. The PGx guided group will have their results reviewed by the clinicians during their treatment and the results may guide clinical decisions. The control group results will be sealed until completion of treatment and clinicians will not have access to this information. These participants will undergo standard treatment dosing and medication selection.

Registry
clinicaltrials.gov
Start Date
October 12, 2018
End Date
April 1, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Molly B. Kraus

Assistant Professor of Anesthesiology

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing primary total knee arthroplasty
  • Patients must understand and provide written informed consent and HIPAA authorization prior to initiation of any study-specific procedures.

Exclusion Criteria

  • Patients with a current diagnosis of chronic pain
  • Patients requiring narcotics for greater than one week prior to surgery
  • Patients with chronic kidney disease with a pre-op creatinine greater than 1.5
  • Patient preference or need for spinal anesthesia rather than general anesthesia
  • Patient planned for robotic surgical approach

Outcomes

Primary Outcomes

Change in Overall Benefit of Analgesic Score (OBAS)

Time Frame: baseline, 48 hours following PACU discharge

The overall benefit of analgesia score (OBAS) is a daily multi-dimensional survey that assesses analgesia benefits, opioid-related adverse events (ORAEs), and patient satisfaction. It is a seven-item scale, with items ranging from( 0 = not at all) to(4 = very much). To calculate the Total OBAS score, compute the sum of scores in items 1-6 and add '4-score in item 7'. Low score indicates high benefit.

Secondary Outcomes

  • Change in prescription pattern for postoperative pain control.(baseline, 48 hours following PACU discharge)
  • Change in Opioid requirements(baseline, 48 hours following PACU discharge)
  • Changes in opioid use perioperatively based on pharmacogenomic testing(baseline, 48 hours following PACU discharge)

Study Sites (1)

Loading locations...

Similar Trials